Study #2016-0033
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) plus Anti-CTLA-4 (Tremelimumab) in Patients with Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Durvalumab, Tremelimumab
Description
This pilot phase I trial studies the side effects of durvalumab and tremelimumab in treating patients with muscle-invasive, high-risk urothelial cancer that cannot be treated with cisplatin-based therapy before surgery. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
Study phase:
Phase I (Early)
Physician name:
Jianjun Gao
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-485-3674
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.